| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Research and Development
1 company
Heather Raymon is SVP, Research and Development at ARTV. Heather Raymon's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $623K at current prices.
The ARTV filings lean toward selling, a net 3,095 shares.
Heather Raymon has 7 Form 4 filings on record from September 2024 to May 2026, all as SVP, Research and Development at Artiva Biotherapeutics (ARTV), 2024–2026.
The 14 reported transactions were 5 dispositions back to the company, 4 stock awards, 4 tax withholdings and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $28K.
The only open-market sale was 3,095 shares of ARTV at an average $9.01 on May 19, 2026, about $28K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 | ARTV Artiva Biotherapeutics, Inc. | SVP, Research and Development | Sell | 3,095 | $9.01 | $27,879.14 | -2.0% | +37.3% | - |